Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004747 | 0.92 | RAB9A (0.48) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL15485748 | 0.92 | KDM4E (0.47) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL1545976 | 0.89 | HTR2C (0.50) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL29869220 | 0.89 | HTR2C (0.50) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL6745979 | 0.88 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL30619334 | 0.88 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL1545709 | 0.85 | HTR2A (0.50) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL25270970 | 0.83 | KDM4E (0.46) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL8206962 | 0.83 | KCNH2 (0.49) | KDM4EGAAPDPK1CYP3A4ALDH1A1 | |
| SCHEMBL10395724 | 0.83 | MAPK8 (0.44) | KDM4EGAAPDPK1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-119156381-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117050062-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023193760-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2023-10-12 | — | — | WO | disclosed |
| CN-111187221-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111171000-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2011-09-01 | — | — | US | disclosed |
| US-7951832-B2 | Pyrazole derivatives as kinase inhibitors | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-31 | — | — | US | disclosed |
| CN-101910133-A | Heterocyclic phenylamide T-type calcium channel antagonists | MERCK & CO INC | 2010-12-08 | — | — | CN | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2007058626-A1 | INDAZOLE COMPOUNDS | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124621-A1 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | BRAF, MAP3K1, MAP3K3 | KDM4E 784/4885GAA 2078/4885PDPK1 29/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | KDM4E 3268/4885GAA 11/4885PDPK1 1459/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | KDM4E 2150/4885GAA 13/4885PDPK1 1179/4885 |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | KDM4E 3129/4885GAA 2018/4885PDPK1 1288/4885 |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | KDM4E 2230/4885GAA 3565/4885PDPK1 530/4885 |
| US-20110212961-A1 | Pyrazole Derivatives as Kinase Inhibitors | BRAF, MAP3K1, MAP3K3 | KDM4E 784/4885GAA 2078/4885PDPK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.